Cargando…
A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase
Valosin-containing protein (VCP/p97) ATPase (a.k.a. Cdc48) is a key member of the ER-associated protein degradation (ERAD) pathway. ERAD and VCP/p97 have been implicated in a multitude of human diseases, such as neurodegenerative diseases and cancer. Inhibition of VCP/p97 induces proteotoxic ER stre...
Autores principales: | Segura-Cabrera, Aldo, Tripathi, Reshmi, Zhang, Xiaoyi, Gui, Lin, Chou, Tsui-Fen, Komurov, Kakajan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359624/ https://www.ncbi.nlm.nih.gov/pubmed/28322292 http://dx.doi.org/10.1038/srep44912 |
Ejemplares similares
-
Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors
por: Bastola, Prabhakar, et al.
Publicado: (2017) -
P97/VCP ATPase inhibitors can rescue p97 mutation-linked motor neuron degeneration
por: Wang, F, et al.
Publicado: (2022) -
The Role of the N-Domain in the ATPase Activity of the Mammalian AAA ATPase p97/VCP
por: Niwa, Hajime, et al.
Publicado: (2012) -
How Viruses Use the VCP/p97 ATPase Molecular Machine
por: Das, Poulami, et al.
Publicado: (2021) -
AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential
por: Vij, Neeraj
Publicado: (2008)